---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-039645"
form_type: "8-K"
ticker: "CING"
cik: "0001862150"
company_name: "Cingulate Inc."
filed_at: "2024-10-07T23:59:59+00:00"
generated_at: "2026-05-30T19:36:43.796495+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cingulate raises $11.7M, extends cash runway through Q2 2025; NDA for CTx-1301 targeted mid-2025

## Summary
- Raised approximately $11.7 million in capital during August and September 2024.
- Cash and cash equivalents of approximately $10 million as of September 30, 2024.
- Cash runway extended through second quarter of 2025 to fund clinical, manufacturing, and regulatory activities.
- NDA filing for CTx-1301 targeting mid-2025 for potential FDA approval.

## SEC filing metadata
- accession: 0001493152-24-039645
- form_type: 8-K
- ticker: CING
- cik: 0001862150
- company_name: Cingulate Inc.
- filed_at: 2024-10-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1862150/000149315224039645/0001493152-24-039645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1862150/000149315224039645/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-039645
- JSON: https://secwatch.observer/filing/0001493152-24-039645.json
- Plain text: https://secwatch.observer/filing/0001493152-24-039645.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.